Tidal Investments LLC Sells 12,598 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tidal Investments LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 61.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,978 shares of the biopharmaceutical company's stock after selling 12,598 shares during the period. Tidal Investments LLC's holdings in Halozyme Therapeutics were worth $381,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $29,000. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust grew its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded down $2.33 during trading hours on Tuesday, hitting $53.31. The company's stock had a trading volume of 3,099,309 shares, compared to its average volume of 1,644,997. The stock has a fifty day simple moving average of $58.52 and a 200-day simple moving average of $55.71. The company has a market capitalization of $6.57 billion, a P/E ratio of 15.54, a PEG ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Halozyme Therapeutics's revenue was up 35.2% compared to the same quarter last year. During the same period last year, the firm posted $0.79 earnings per share. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HALO. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Finally, Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Hold" and an average target price of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the transaction, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.